- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas
© Karihtala et al; licensee BioMed Central Ltd. 2011
Received: 14 December 2010
Accepted: 21 June 2011
Published: 21 June 2011
Triple-negative breast cancer (TNBC) and basal-like breast cancer (BLBC) are breast cancer subtypes with an especially poor prognosis. 8-Hydroxydeoxyguanosine (8-OHdG) is a widely used marker of oxidative stress and the redox-state-regulating enzymes peroxiredoxins (PRDXs) are efficient at depressing excessive reactive oxygen species. NF-E2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) are redox-sensitive transcription factors that regulate PRDX expression. This is the first study to assess oxidative stress and or cell redox state-regulating enzymes in TNBC and BLBC.
We assessed immunohistochemical expression of 8-OHdG, Nrf2, Keap1, PRDX III and PRDX IV in 79 women with invasive ductal breast carcinomas. Of these tumors, 37 represented TNBC (grade II-III tumors with total lack of ER, PR and human epidermal growth factor receptor 2 [HER2] expression). Control cases (n = 42) were ER-positive, PR-positive and HER2-negative. Of the 37 TNBCs, 31 had BLBC phenotype (TNBC with expression of cytokeratin 5/6 or epidermal growth factor receptor 1).
Patients with TNBC had worse breast cancer-specific survival (BCSS) than the control group (p = 0.015). Expression of 8-OHdG was significantly lower in TNBC than in the non-TNBC group (p < 0.005). 8-OHdG immunostaining was associated with better BCSS (p = 0.01), small tumor size (p < 0.0001) and low grade (p < 0.0005). Keap1 overexpression was observed in the TNBC cohort (p = 0.001) and Keap1-positive patients had worse BCSS than Keap1-negative women (p = 0.014). PRDX IV was overexpressed in the TNBC vs. the non-TNBC group (p = 0.022).
Cellular redox state markers may be promising targets when elucidating the pathogenesis of TNBC.
Breast cancers lacking both estrogen and progesterone receptors (ER and PR), with simultaneous absence of human epidermal growth factor 2 receptor (HER2) are defined as triple-negative breast cancers (TNBCs). Currently there are no targeted therapies available for TNBC and chemotherapy is the only option in both adjuvant and metastatic settings. TNBC has a poor prognosis in terms of disease-free survival and overall survival and it tends to be associated with aggressive and early recurrence . Some TNBCs have a basal-like phenotype, and these basal-like breast cancers (BLBCs) show simultaneous expression of cytokeratin (CK) 5/6 or epidermal growth factor-1 (EGFR-1) . It has been suggested that BLBCs may have a different pathogenesis, originating probably from mammary epithelial luminal progenitor cells .
Reactive oxygen species (ROS) are continuously produced in all aerobic organisms as a consequence of aerobic respiration. Although many ROS are vital regulators of signaling pathways, oxidative stress occurs if ROS production exceeds the capacity of the ROS-suppressing machinery, which mainly consists of antioxidant enzymes. Oxidative stress is a potent cause of damage in all cellular macromolecules and it may also lead to carcinogenesis . The hydroxyl radical (•OH) is the most unstable ROS and its interaction with DNA leaves a specific and stable footprint, 8-hydroxydeoxyguanosine (8-OHdG i.e. 8-oxodG), which can be reliably assessed by means of immunohistochemistry, for example.
Peroxiredoxins (PRDXs) I-VI are one of the most important antioxidant enzymes and they also modulate intracellular signaling pathways related to apoptosis and cell proliferation . The main antioxidant function of PRDXs is to reduce peroxides, including H2O2, to corresponding alcohols and water. If H2O2 is not reduced and it interacts with transition metals (usually ions of Fe or Cu), •OH and consequently 8-OHdG can be formed. PRDXs are strongly induced in oxidative conditions. This induction is largely mediated by redox-sensitive NF-E2-related factor 2 (Nrf2), which under oxidative stress translocates to the nucleus and attaches to antioxidant response elements (AREs) of antioxidant genes, thus stimulating synthesis of respective proteins [6–8]. Nrf2 is negatively regulated by another redox-sensitive protein, Kelch-like ECH-associated protein 1 (Keap1).
Estrogens are important ROS inducers in ER-positive breast cancer cells , although data from clinical series is lacking. Our previous results have suggested that two of the most important regulators of the cellular redox state, PRDX III and PRDX IV, may have special roles in steroid receptor-negative breast cancers . This study was designed to find out whether or not oxidative stress and/or cell redox state-regulating enzymes have special roles in TNBC and BLBC. These breast cancer subtypes are especially aggressive and more accurate prognostic and predictive biomarkers are urgently required.
The material consisted of 79 women with local or locally advanced breast cancer from a prospective series at Oulu University Hospital, Oulu, Finland, diagnosed during 2000-2008. All tumors showed invasive ductal histology. The specimens had been fixed in neutral formalin, embedded in paraffin blocks and stored at the Department of Pathology at the same institute. The patients were surgically staged according to the current TNM classification system and the histological degree of tumor differentiation was classified according to the WHO Classification of Tumours . The study was approved by the Local Ethics Committee of the Northern Ostrobothnia Hospital District of Finland.
Immunohistochemistry and scoring
Immunohistochemical methods used in this study.
Antibody (Clone/Product code)
Source of primary antibody
CK5/6 (D5/16 B4)
Dako Envision Kit
DakoCytomation, Glostrup, Denmark
Dako Envision Kit
Leica Biosystems, Newcastle, United Kingdom
Dako Envision Kit
Novocastra, Newcastle upon Tyne, United Kingdom
Dako Envision Kit
PR (PgR 636)
Dako Envision Kit
PRDX III (LF-P A 0030)
Histostain-Plus Bulk Kit
Labfrontier, York, United Kingdom
PRDX IV (LF-P A 0009)
Histostain-Plus Bulk Kit
Dako Envision Kit
JaICA, Fukuroi, Japan
Histostain Plus Broad Spectrum Kit
Santa Cruz Biotechnology, Santa Cruz, USA
Biocare Medical HRP Polymer Kit
Tumors exhibiting nuclear estrogen/progesterone receptor expression in more than 10% of invasive tumor cells were considered as steroid receptor-positive. The TNBC group did not show any ER- or PR-positivity. Membranous HER2 expression was also studied by means of immunohistochemistry (IHC) and if a specimen exhibited a HER2-positive result (1+ to 3+ on a scale of 0 to 3+) in IHC, Her2 gene amplification status was determined by means of chromogenic in situ hybridization (CISH). Breast cancers with six or more gene copies of Her2 in cells were considered HER2-positive . Expression of Ki-67 was studied immunohistochemically as described previously, the cut-off for negativity being <5% . Cytokeratin 5/6 was scored positive if any (weak or strong) cytoplasmic and/or membranous invasive carcinoma cell staining was observed and EGFR was scored positive if there were more than 10% of positive cells.
When comparing PRDXs with each other or against tumor parameters or survival, cytoplasmic PRDX immunostaining was divided into two groups, as in our previous breast cancer study : 0 = absent or weak staining and 1 = moderate or strong staining. Since 97.5% of the cases were negative or only weakly positive for nuclear PRDX III, this parameter was divided into either negative or any amount of positive staining for further statistical analyses. Interpretation of 8-OHdG immunostaining was similar to that used for cytoplasmic PRDXs, but only nuclear 8-OHdG staining was evaluated. In the case of Nrf2, nuclear immunopositivity, and in the case of Keap1 both nuclear and cytoplasmic immunopositivity were considered as a positive result.
Patient and tumor characteristics.
SPSS 17.0.2 for Windows was applied for statistical analysis. The reported p-values are from 2-sided Pearson chi-square tests, except for survival analysis. Survival was analyzed by using Kaplan-Meier curves with the log-rank test and only breast cancer-related death was used as an endpoint. Cox regression analysis was used in multivariate analysis. T-class was divided in statistical analyses to either T1 or larger and grade was divided into either grade I-II or grade III. Probability values below 0.05 were considered significant.
Number of positive immunostaining results in different subgroups and corresponding p-values.
Cytoplasmic PRDX III
Nuclear PRDX III
Cytoplasmic PRDX IV
8-OHdG was overexpressed in the ER+/PR+/HER2- group compared with TNBC samples (p = 0.0016) (Table 3). Keap1 immunostaining was more prevalent in the TNBC group than in the control group (p = 0.0011). Cytoplasmic PRDX III showed a trend towards less frequent expression in the TNBC cohort (p = 0.10). In addition, a lack of nuclear PRDX III expression was more frequently observed in the triple-negative carcinomas compared with the ER+/PR+/HER2- control specimens (p = 0.060). On the other hand, cytoplasmic PRDX IV was overexpressed in the triple-negative breast carcinomas, compared with the non-TNBC group (p = 0.022).
Immunostaining of Nrf2 and Keap1 showed significant co-expression (p = 0.0037). Nrf2 and PRDX III were significantly co-expressed when all cases were considered (p = 0.008) and also in non-TNBC-cases (p = 0.011), but not in the TNBC group alone (p = 0.201). PRDX III expression in nuclei was independent of its presence in cytoplasm. PRDX IV expression was not significantly associated with PRDX III expression (p = 0.068 for expression in the same samples). Expression of 8-OHdG was not associated with antioxidant enzymes when all samples were considered. However, 8-OHdG expression had a significant association with low cytoplasmic PRDX III expression in TNBC cases (p = 0.018), but in non-TNBC cases there was an association with the presence of cytoplasmic PRDX III expression (p = 0.028).
8-OHdG immunostaining was associated highly significantly with the traditional factors of good prognosis (low grade p = 0.00020, low T-class p = 0.00065). Keap1 was overexpressed in grade III tumors (p = 0.0058) and near-significantly in high Ki-67 tumors (p = 0.075). Nuclear PRDX III expression was associated with less aggressive tumor characteristics, since it was overexpressed within the T1 tumor population (p = 0.011) and in grade I-II disease (p = 0.029).
8-OHdG-positive immunostaining was associated with better breast cancer-specific survival (BCSS) when all patients were taken into account (p = 0.01). Keap1-positive patients had shorter BCSS than those with Keap1-negative tumors (p = 0.014). Cytoplasmic PRDX III immunostaining had a nearly significant association with poorer BCSS (p = 0.06). In multivariate analysis none of the studied markers were independent from traditional prognostic factors.
There is great variability in the reported frequencies of triple-negative and basal-like breast cancers in the literature, depending on the criteria used. The prevalence of TNBC has ranged from 17.1% to 30.5% and that of BLBC from 8.0% to 55.7% . Here we reassessed the steroid receptor status and HER2 status of tumors; those tumors without any ER and PR immunostaining were considered as receptor negative and tumors exhibiting more than 10% of invasive tumor cells were considered as steroid receptor-positive. In addition, only grade II-III tumors with ductal histology were included in the TNBC cohort. It is also known that triple-negative and basal-like subtypes of breast carcinoma are not single cohesive entities but instead reflect a collection of different diseases. Outcome in cases of TNBC has consistently been worse compared with ER- and PR-positive tumors, which was again confirmed in the current material. TNBC and BLBC tumors are usually larger and of higher grade compared with receptor-positive breast cancer tumors and some reports suggest that cases of BLBC are more often node-negative [3, 14–16]. In the current study, triple-negative carcinomas were larger than ER+/PR+/HER2- cancers, as were basal-like carcinomas compared to non-basal-like triple-negative breast cancers, but no association with nodal status was observed. The proportion of basal-like subtype showing cancers in our material is in line with previous reports .
One of the most important estrogen-related carcinogenic mechanisms is oxidative metabolism of estrogen and subsequent formation of ROS [17, 18]. Published data from several laboratories suggest that in vitro, physiological estrogen concentrations induce significant oxidative stress and that estrogen-induced ROS formation takes place in mitochondria in particular [19, 20]. Other studies have provided evidence that 8-OHdG levels in the ER-positive MCF-7 breast cancer cell line are over 9-fold higher than in triple-negative MDA-MB-231 cells  and inhibition of estrogen receptor alpha expression significantly reduces estrogen-induced 8-OHdG formation in MCF-7 cells . Since estrogen levels in ER-positive tumors are higher than in ER-negative ones , our finding that 8-OHdG (as a marker of ROS-derived DNA damage) was highly overexpressed in the ER+/PR+/HER2- group (73.2%) compared with TNBCs (37.1%) is in line with the above data. Previous and current data taken together suggest that ROS play a major role in steroid receptor-positive breast cancer pathogenesis in particular, but not necessarily in cases of TNBC (including BLBC).
A negative prognostic value of immunohistochemical 8-OHdG expression has been reported in connection with at least colorectal carcinoma , ovarian cancer  and malignant melanoma . Nevertheless, there is a growing body of evidence that in breast cancer the prognostic value of 8-OHdG is different. We have recently reported that immunohistochemical 8-OHdG expression is an independent factor related to good prognosis in breast cancer, especially as regards ductal histology . In another previous study we found that 8-OHdG expression was significantly diminished in invasive breast carcinomas compared with non-invasive breast lesions . The current data confirm previous results, as 8-OHdG was a marker of good BCSS also in the current population.
When cells are exposed to oxidative stress, Keap1 undergoes a modification that allows Nrf2 to be released from a complex with it and translocate to the nucleus where it binds to antioxidant response elements of DNA . Nrf2-mediated antioxidant enzyme induction is one of the major defense mechanisms against excessive ROS production and, on the other hand, PRDX enzymes are considered to be among the most efficient cell redox state-regulating enzymes [8, 28]. The importance of PRDXs is derived partly from their wide subcellular distribution, in contrast to most other antioxidant enzymes. The majority of ROS are produced in mitochondria under physiological conditions and PRDX III is an especially important part of antioxidant defense, since it is located mainly in mitochondria. Peroxiredoxin IV is found in lysosomes, peroxisomes and the endoplasmic reticulum, where oxidative stress is also a potent threat . Previous studies carried out in vitro have demonstrated induction of PRDXs via the Nrf2/Keap1 pathway , but there are no reports on Nrf2 or Keap1 in clinical breast cancer material. The current data is in line with previous in vitro results as regards steroid receptor-positive breast cancer, since there was highly significant co-expression of PRDX III and Nrf2 in ER+/PR+/HER2- cases, which may reflect Nrf2-mediated PRDX induction after estrogen-induced oxidative stress. Furthermore, PRDX III was associated with 8-OHdG expression in the non-TNBC cohort, probably representing antioxidant induction as a response to oxidative imbalance. Keap1 was highly overexpressed in the TNBC group compared with the steroid receptor-positive control group, which implies that there is no need for intensive (Nrf2-mediated) free radical scavenging in cases of TNBC as a result of a lack of estrogen-induced oxidative stress. Keap1-positive tumors were more aggressive than Keap1-negative ones and Keap1 expression associated also to poor prognosis. This probably derives from the sensitive induction of Keap1 in stressed and damaged tumors, rather than carcinogenesis promoting features of Keap1 itself. However, further mechanistic investigations are required to confirm these hypotheses.
In a previous tissue microarray study we reported on PRDX III overexpression in ER- and PR-positive breast cancers and PRDX IV in PR-positive cases . In that study, with unselected breast cancer cases and with older methods of steroid receptor assessment, PRDX III- and PRDX IV-positive cases were associated with better prognosis. In the current material neither of the studied PRDX enzymes showed significant association with survival. We observed PRDX IV overexpression in TNBC, especially in non-basal-like breast cancers. PRDX III expression was similar in the TNBC and non-TNBC groups, but PRDX III-positive tumors tended to be smaller and of lower grade. This association with lower grade was observed in a previous study  and suggests a protective role of this mitochondrial enzyme in breast carcinogenesis. All in all, PRDXs III and IV could function as protective enzymes in ER- and PR-positive breast carcinomas, working against the ROS induction of estrogen metabolites.
To summarize, the current results, together with previous preclinical observations, suggest that estrogen induces significant oxidative stress in ER+/PR+ breast cancer compared with TNBC. The Nrf2/Keap1 pathway is more active in steroid receptor-positive disease and this subsequently causes induction of antioxidant defense that is not observed in TNBC. Further studies with larger patient groups are required to elucidate possible prognostic roles of the studied factors.
The authors thank Mr. Manu Tuovinen, Ms Aija Parkkinen and Mr. Kari Mononen for their excellent technical assistance. The study was financially supported by the Finnish Medical Foundation (PK), the Orion-Farmos Foundation (PK), the Finnish Anti-Tuberculosis Association (YS) and the KEVO Funding of Northern Savo (YS) and Northern Ostrobothnia Hospital Districts (AJV, SK).
- Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009, 20: 1913-1927. 10.1093/annonc/mdp492.View ArticlePubMedGoogle Scholar
- Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14: 1368-1376. 10.1158/1078-0432.CCR-07-1658.View ArticlePubMedGoogle Scholar
- Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010, 7: 403-417. 10.1016/j.stem.2010.07.010.View ArticlePubMedGoogle Scholar
- Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, Walborg EF: The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect. 1998, 106 (Suppl 1): 289-295. 10.1289/ehp.98106s1289.View ArticlePubMedPubMed CentralGoogle Scholar
- Karihtala P, Soini Y: Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS. 2007, 115: 81-103. 10.1111/j.1600-0463.2007.apm_514.x.View ArticlePubMedGoogle Scholar
- Karihtala P, Puistola U: Hypoxia and oxidative stress in the pathogenesis of gynecological cancers and in therapeutical options. Curr Cancer Ther Rev. 2011, 7: 37-55. 10.2174/157339411794474128.View ArticleGoogle Scholar
- Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, Benahmed M, Louisot P, Lunardi J: Response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem. 2002, 277: 19396-19401. 10.1074/jbc.M106585200.View ArticlePubMedGoogle Scholar
- Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res. 2008, 58: 262-270. 10.1016/j.phrs.2008.09.003.View ArticlePubMedPubMed CentralGoogle Scholar
- Musarrat J, Arezina-Wilson J, Wani AA: Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer. 1996, 32: 1209-1214. 10.1016/0959-8049(96)00031-7.View ArticleGoogle Scholar
- Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003, 9: 3418-3424.PubMedGoogle Scholar
- Tavassoli FA, Devilee P, (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, Lyon; IARC Press, 13-59. 63-73Google Scholar
- Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM: Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004, 10: 4793-4798. 10.1158/1078-0432.CCR-0428-03.View ArticlePubMedGoogle Scholar
- Fadare O, Tavassoli FA: The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. 2007, 14: 358-373. 10.1097/PAP.0b013e31814b26fe.View ArticlePubMedGoogle Scholar
- Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foolkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007, 7: 134-10.1186/1471-2407-7-134.View ArticlePubMedPubMed CentralGoogle Scholar
- Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blarney RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004, 203: 661-671. 10.1002/path.1559.View ArticlePubMedGoogle Scholar
- Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 2010, 363: 1938-1948. 10.1056/NEJMra1001389.View ArticlePubMedGoogle Scholar
- Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006, 354: 270-282. 10.1056/NEJMra050776.View ArticlePubMedGoogle Scholar
- Okoh V, Deoraj A, Roy D: Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta. 2011, 1815: 115-33.PubMedGoogle Scholar
- Felty Q, Xiong WC, Sun D, Sarkar S, Singh KP, Parkash J, Roy D: Estrogen induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry. 2005, 44: 6900-6909. 10.1021/bi047629p.View ArticlePubMedGoogle Scholar
- Sastre-Serra J, Valle A, Company MM, Garau I, Oliver J, Roca P: Estrogen downregulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med. 2010, 48: 506-512. 10.1016/j.freeradbiomed.2009.11.025.View ArticlePubMedGoogle Scholar
- Yao Y, Brodie AM, Davidson NE, Kensler TW, Zhou Q: Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat. 2010, 124: 585-591. 10.1007/s10549-010-1023-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Drafta D, Prişcu A, Neacşu E, Gangură M, Schindler AE, Stroe E, Anghel C, Panaitescu G: Estradiol and progesterone receptor levels in human breast cancer in relation to cytosol and plasma estrogen level. J Steroid Biochem. 1983, 18: 459-463. 10.1016/0022-4731(83)90066-3.View ArticlePubMedGoogle Scholar
- Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, O'Donoghue D, Mulcahy H, O'Sullivan J: Nuclear oxidative damage correlates with poor survival in colorectal cancer. Br J Cancer. 2009, 100: 381-388. 10.1038/sj.bjc.6604821.View ArticlePubMedGoogle Scholar
- Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U: DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer. 2009, 19: 1047-1051. 10.1111/IGC.0b013e3181ad0f0d.View ArticlePubMedGoogle Scholar
- Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, Demurtas P, Perra MT, Sirigu P: Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. Oncol Rep. 2010, 23: 329-335.PubMedGoogle Scholar
- Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P: 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer. 2010, 102: 1018-1023. 10.1038/sj.bjc.6605565.View ArticlePubMedPubMed CentralGoogle Scholar
- Karihtala P, Kauppila S, Puistola U, Jukkola-Vuorinen A: Divergent behavior of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology. 2011,Google Scholar
- Ishii T, Yanagawa T: Stress-induced peroxiredoxins. Subcell Biochem. 2007, 44: 375-384. 10.1007/978-1-4020-6051-9_18.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/262/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.